What happens when you take apixaban with fish oil?
Apixaban (brand name Eliquis) is a direct oral anticoagulant. It directly inhibits factor Xa, an enzyme near the end of the coagulation cascade where the cascade converges to make thrombin. By blocking factor Xa, apixaban reduces clot formation and is used in atrial fibrillation, treatment and prevention of venous thromboembolism, and after some orthopaedic surgeries. Unlike warfarin, apixaban does not require routine INR monitoring; its dose is fixed based on indication, age, kidney function, and weight.
Fish oil supplements contain the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). At physiological doses, EPA and DHA become incorporated into platelet cell membranes. Once incorporated, they shift the balance of prostaglandins and thromboxanes platelets produce, mildly reducing the tendency of platelets to clump together. This is a real but generally modest antiplatelet effect, separate from the way apixaban works.
A 2024 systematic review and meta-analysis published in the Journal of the American Heart Association (Javaid et al.) pooled data from 11 randomised trials and 120,643 patients. The headline finding was reassuring at typical supplement doses: omega-3 PUFAs were not associated with a significant increase in total bleeding or central nervous system bleeding compared with control. However, very high doses, in particular 4 g per day of purified EPA (icosapent ethyl, brand name Vascepa) used in trials such as REDUCE-IT, were associated with a small absolute increase in bleeding events of roughly 0.6%. Bleeding risk correlated more closely with EPA dose than with background antiplatelet therapy.
Why is this important?
The reason this combination deserves attention is not because typical fish oil routinely causes bleeding with apixaban, but because the dose range across the supplement market is huge. A drugstore fish oil softgel might contain 300 mg of combined EPA+DHA. A high-potency triglyceride-form omega-3 might deliver 1,000-2,000 mg per softgel. A prescription product like icosapent ethyl is dosed at 4 g per day. The bleeding signal in the 2024 meta-analysis was concentrated in the high-dose end of that spectrum.
Apixaban already raises bleeding risk on its own; that is the cost of its benefit in preventing strokes and clots. Adding a high-dose omega-3 product piles a measurable, though small, additional risk on top. For older patients, those with kidney impairment, and those also on aspirin or an antiplatelet for coronary disease, even small additional bleeding risk can matter clinically.
The other reason to be careful is that omega-3 effects, like other antiplatelet effects, are not detectable on routine labs. Apixaban does not have a routine monitoring blood test the way warfarin does, so there is no INR to flag a problem. The first sign of trouble is usually clinical: a bruise that grows, a nosebleed that will not stop, blood in stool or urine.
What should you do?
Tell the clinician who manages your apixaban about every supplement you take, including fish oil. For most adults, a standard fish oil dose of under 1 g per day of combined EPA+DHA is generally considered low-risk on apixaban, and many cardiologists routinely allow it. Doses up to 3 g per day appear not to raise bleeding risk significantly in the pooled data, but they should still be discussed with the prescriber.
Do not start a 4 g per day prescription-strength omega-3 (icosapent ethyl, omega-3 acid ethyl esters) without explicit guidance from the doctor managing your apixaban. If you are on one for hypertriglyceridaemia or cardiovascular risk reduction, this is a coordination question, not a self-management question.
Watch for bleeding signs and contact your prescriber promptly if any appear: a nosebleed lasting more than 10 minutes, bleeding gums when brushing, pink or red urine, black or tarry stools, coffee-ground vomiting, large new bruises, prolonged bleeding from small cuts, heavy menstrual bleeding, severe headache, new weakness or numbness, or change in vision. Severe symptoms warrant an emergency room visit.
Before elective surgery or dental work, tell the team about fish oil use along with the apixaban. Many surgeons ask patients to stop fish oil 5-7 days before a procedure as part of the perioperative plan, in tandem with the apixaban hold.
Which specific products are affected?
The interaction note covers oral omega-3 products of all kinds: standard fish oil softgels, krill oil, algal oil, cod liver oil, high-concentration triglyceride or ethyl-ester fish oil, and prescription products including icosapent ethyl (Vascepa) and omega-3 acid ethyl esters (Lovaza, Omtryg). The relevant number to look at on the label is total EPA + DHA per serving, not the total fish oil per softgel.
Eating fatty fish like salmon, mackerel, sardines, or trout a few times a week as part of a normal diet has not been associated with bleeding on apixaban and is generally encouraged for cardiovascular health. The bleeding signal is tied to concentrated supplement doses, particularly at the very high end.
The bottom line
Fish oil omega-3s have a mild antiplatelet effect that can theoretically add to apixaban's bleeding risk. Pooled trial data show no significant bleeding increase at typical supplement doses, but a small absolute increase at very high doses (around 4 g per day of pure EPA). Most adults on apixaban can take standard fish oil with their prescriber's awareness. Avoid high-dose prescription-strength omega-3 without explicit clinician approval. Report any unusual bleeding promptly and tell surgeons and dentists about both apixaban and fish oil.